Regeneron reports Q4 profit, revenue beats [MarketWatch]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: MarketWatch
Regeneron reports Q4 profit, revenue beats Regeneron Pharmaceuticals Inc. REGN, -1.24% reported fourth-quarter profit and revenue beats early Thursday. Earnings for the latest quarter declined to $174 million, or $1.50 per share, from $253 million, or $2.19 per share in the year-earlier period. Adjusted earnings-per-share were $5.23, compared with the FactSet consensus of $4.48. Revenue rose to $1.58 billion from $1.23 billion, compared with the FactSet consensus of $1.50 billion. Eyelea U.S. sales and sales of Praluent and Dupixent, two collaborations between Regeneron and Sanofi SNY, -4.08% beat the FactSet consensus. Arcalyst sales matched the consensus and sales of Kevzara and Zaltrap, which are also Sanofi collaborations, missed. Regeneron shares lifted 0.2% in premarket trade. Company shares have plummeted 19.4% over the last three months, compared with a 3.4% rise in the S&P 500 SPX, -0.50%
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Medigene AG reports Financial Results and Business Update for Q1 2024 [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Regeneron (REGN) Reports Next Week: What You Should Expect [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Yahoo! Finance]Yahoo! Finance
- AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Reuters]Reuters
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- REGN's page on the SEC website